Hayes, Sarah H.
Liu, Qingfan
Selvakumaran, Sureka
Haney, Matthew J.
Batrakova, Elena V.
Allman, Brian L.
Walton, Paul A.
Kiser, Patti
Whitehead, Shawn N.
Funding for this research was provided by:
Weston Brain Institute
Article History
Received: 6 November 2020
Revised: 12 May 2021
Accepted: 18 June 2021
First Online: 1 July 2021
Declarations
:
: The recombinant enzyme CAT-SKL is covered by United States patent 7601366 and 8663630 to P.A. Walton and S.R. Terlecky, who have no commercial or equity interests in the CAT-SKL molecule at this time. Other authors state no conflict of interest.